{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:45:21Z","timestamp":1788432321752,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatopathology"],"abstract":"<jats:p>Dupilumab is a humanized IgG4 monoclonal-antibody that is approved by the United States Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older. In recent years, several case studies have associated the unmasking or progression of cutaneous T-cell lymphomas (CTCL) with dupilumab treatment. To date, all reported cases of dupilumab-associated CTCL have shown a CD4+ T-helper-cell-predominant immunophenotype. Here, we report a case of a 72-year-old man who presented with a 2-year history of a diffuse, pruritic eruption, who was started on dupilumab for 9 weeks. He subsequently developed mycosis fungoides (MF) with a CD8+-predominant immunophenotype. Overall, cases of CD8+ mycosis fungoides are less common and relatively less understood than their CD4+ counterparts, with varied presentations and courses. We present a case of dupilumab-associated CD8+ MF to highlight this presentation for pathologists and providers.<\/jats:p>","DOI":"10.3390\/dermatopathology9040045","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:46:41Z","timestamp":1669798001000},"page":"385-391","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dupilumab-Associated Mycosis Fungoides with a CD8+ Immunophenotype"],"prefix":"10.3390","volume":"9","author":[{"given":"Ariel","family":"Park","sequence":"first","affiliation":[{"name":"Department of Dermatology, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Irvine, CA 92697, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Elsensohn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","article-title":"A review of dupilumab in the treatment of atopic diseases","volume":"15","author":"Thibodeaux","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1097\/DER.0000000000000679","article-title":"Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient with a History of Atopic Dermatitis","volume":"32","author":"Ayasse","year":"2020","journal-title":"Dermatitis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.12788\/cutis.0074","article-title":"Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma","volume":"106","author":"Hollins","year":"2020","journal-title":"Cutis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"adv00271","DOI":"10.2340\/00015555-3576","article-title":"Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas","volume":"100","author":"Lazaridou","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13880","DOI":"10.1111\/dth.13880","article-title":"Progression of mycosis fungoides after treatment with dupilumab: A case report","volume":"33","author":"Miyashiro","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D3271052041","article-title":"Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab","volume":"27","author":"Newsom","year":"2021","journal-title":"Dermatol. Online J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0959-8049(19)30628-8","article-title":"A case of mycosis fungoides with large cell transformation following dupilumab treatment","volume":"119","author":"Poyner","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","article-title":"Acceleration of cutaneous T-cell lymphoma following dupilumab administration","volume":"8","author":"Russomanno","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/DAD.0000000000001875","article-title":"Evolution of Dupilumab-Associated Cutaneous Atypical Lymphoid Infiltrates","volume":"43","author":"Sokumbi","year":"2021","journal-title":"Am. J. Dermatopathol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tran, J., Morris, L., Vu, A., and Duvic, M. (2020). Development of S\u00e9zary syndrome following the administration of dupilumab. Dermatol. Online J., 26.","DOI":"10.5070\/D3264048364"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1111\/1346-8138.15501","article-title":"Dupilumab therapy in S\u00e9zary syndrome misdiagnosed as atopic dermatitis: A case report","volume":"47","author":"Umemoto","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Park, A., Wong, L., Lang, A., Kraus, C., Anderson, N., and Elsensohn, A. (2022). Cutaneous T-cell lymphoma following dupilumab use: A systematic review. Int. J. Dermatol., 1\u201315.","DOI":"10.1111\/ijd.16388"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40521-019-00218-x","article-title":"Dupilumab in atopic dermatitis","volume":"6","year":"2019","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2020.03.051","article-title":"Dupilumab and cutaneous T-cell lymphoma","volume":"83","author":"Elston","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.alit.2020.01.005","article-title":"Implications of IL-13R\u03b12 in atopic skin inflammation","volume":"69","author":"Furue","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1010428318783657","DOI":"10.1177\/1010428318783657","article-title":"Interleukin-13 receptor alpha 2 expression in tumor cells is associated with reduced disease-free survival in patients with luminal subtype invasive breast cancer","volume":"40","author":"Kwon","year":"2018","journal-title":"Tumour. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shi, J., Song, X., Traub, B., Luxenhofer, M., and Kornmann, M. (2021). Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062998"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/0008-5472.CAN-07-5301","article-title":"Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2","volume":"68","author":"Terabe","year":"2008","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1046\/j.1365-2133.2000.03888.x","article-title":"CD8-positive juvenile onset mycosis fungoides: An immunohistochemical and genotypic analysis of six cases","volume":"143","author":"Whittam","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1365-2133.2008.08761.x","article-title":"The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality","volume":"159","author":"Massone","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0560.2008.01259.x","article-title":"CD8-positive mycosis fungoides and primary cutaneous aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma","volume":"36","author":"Diwan","year":"2009","journal-title":"J. Cutan. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ijd.14689","article-title":"CD8+ cytotoxic mycosis fungoides: A retrospective analysis of clinical features and follow-up results of 29 patients","volume":"59","author":"Sanli","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2017.05.015","article-title":"CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder","volume":"77","author":"Kantor","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"}],"container-title":["Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2296-3529\/9\/4\/45\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:04Z","timestamp":1760146204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2296-3529\/9\/4\/45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["dermatopathology9040045"],"URL":"https:\/\/doi.org\/10.3390\/dermatopathology9040045","relation":{},"ISSN":["2296-3529"],"issn-type":[{"value":"2296-3529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}